Halozyme Therapeutics, Inc. (HALO)

Market Cap	4.67B
Revenue (ttm)	660.12M
Net Income (ttm)	202.13M
Shares Out	135.37M
EPS (ttm)	1.44
PE Ratio	23.95
Forward PE	23.47
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,629,537
Open	33.59
Previous Close	33.68
Day's Range	33.42 - 34.74
52-Week Range	32.83 - 59.46
Beta	1.26
Analysts	Buy
Price Target	57.76 (+67.47%)
Earnings Date	May 9, 2023

About HALO

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcu...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 145
• Stock Exchange: NASDAQ
• Ticker Symbol: HALO

Financial Performance

In 2022, HALO's revenue was $660.12 million, an increase of 48.91% compared to the previous year's $443.31 million. Earnings were $202.13 million, a decrease of -49.81%.

Analyst Forecast

According to 16 analysts, the average rating for HALO stock is "Buy." The 12-month stock price forecast is $57.76, which is an increase of 67.47% from the latest price.

Price Target

$57.76

(67.47% upside)

Analyst Consensus: Buy